PR Projects
At Orbit Dot, we measure our success not by the deliverables we produce, but by the clinical and societal impact we drive.
Operating at the intersection of public health, policy advocacy, and corporate strategy, our campaigns are designed to move the needle in Hong Kong's highly regulated healthcare landscape.
Disease Awareness Campaign
"Life Has No Plan B" —
Citywide B-Cell Lymphoma Awareness Campaign
With the rising threat of B-cell lymphoma in Hong Kong, urgent public education was required. However, traditional medical education frameworks were failing to effectively reach the most vulnerable demographics: the elderly and their primary caregivers.
Launched on April 22, 2026, we shattered traditional clinical boundaries by rolling out a comprehensive 360-degree OOH advertisement at MTR stations, online-to-offline (O2O) strategy across Metro Broadcast & AM730 newspaper. We transformed complex disease markers into an accessible, urgent public health narrative tailored for local communities.
Successfully bridged the gap between clinical urgency and public awareness, driving critical health information directly into the hands of the public and sparking vital conversations between patients and HCPs.
Check out the campaign website: https://www.b-cell-lymphomas.com
Community & Patient Advocacy
Advocacy in Action: Championing a "Green Channel" for Faster Drug Access
Despite the introduction of the "1+" drug approval mechanism, patients in Hong Kong continued to face agonizing, life-threatening wait times for innovative cancer treatments. The system required an urgent, unified voice to push for faster access.
We mobilized a high-impact Health PR and advocacy campaign, bringing together authoritative voices: Tim Pang from the Society for Community Organization (SoCO) and Mr. Chan Wai-kit, Chairman of the Cancer Patient Alliance. Together, we amplified the urgent call for a "Green Channel" (綠色通道) and an "approve first, review later" policy.
Elevated a critical life-or-death issue to the forefront of Hong Kong's healthcare policy debate, demonstrating our ability to drive meaningful public affairs, unify patient advocacy groups, and shape clinical access narratives.
Check out the coverage HERE
Corporate Communications
Amplifying Corporate Vision:
BeOne Medicines C-Suite Media Feature
BeOne Medicines needed to articulate a powerful global rebranding and communicate a highly complex corporate mission—tackling the high costs and long development cycles of innovative cancer treatments—to the Hong Kong market.
We secured and structured an exclusive thought-leadership feature on HK01 with Dr. Wu Xiaobin, President and COO of BeOne Medicines. We strategically drove key narratives around global clinical networks, differential pricing, and global health accessibility.
Successfully positioned BeOne Medicines as a global innovator with profound local impact, anchoring their new brand identity under a powerful, widely-read manifesto: "Cancer has no borders, neither do we."
Check out the coverage HERE
Product Market Access
Driving Healthcare Equity and
Urging Drug Reimbursement to Hospital Authority
Despite clear clinical evidence supporting next-generation BTK inhibitors (BTKi) for Chronic Lymphocytic Leukaemia (CLL), a significant barrier remained: a lack of subsidized access. Patients in Hong Kong were forced to navigate a system where life-extending, highly tolerable therapies were financially out of reach, often leaving them reliant on older, harsher treatments.
The Strategy: We spearheaded a targeted advocacy campaign and press conference to put immediate, public pressure on the Hospital Authority (HA). By partnering with Dr. Herman Liu (Haematologist), we framed this lack of access as an urgent healthcare equity crisis.
By unifying the patient community and leveraging robust clinical data, we successfully campaigned to add the next-generation BTKi to the Hospital Authority (HA) Drug Formulary. Crucially, we secured Safety Net reimbursement, ensuring qualified CLL patients now have equitable, low-cost access to this life-extending therapy.
Check out the earned coverage HERE
